Avalo Therapeutics to Participate in Upcoming Investor Conferences

WAYNE, Pa. and ROCKVILLE, Md., May 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in June.

Jefferies Global Healthcare Conference 2025, New York
Fireside Chat
June 4, 2025, at 7:35 am ET

Oppenheimer Innovators in I&I Summit, New York
Panelist: “Dermatology: AA, HS, PSO”
June 25, 2025, at 10am ET

Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. For more information about Avalo, please visit www.avalotx.com.

About AVTX-009 

AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology.

For media and investor inquiries
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
[email protected] 
410-803-6793

or

Meru Advisors
Lauren Glaser
[email protected] 

You May Also Be Interested In

• Northeast Ohio Medical University (NEOMED) Mobilizes Global Health Resources for Nepal Disaster Response and Recovery
• LithiumBank Announces Closing of Upsized Private Placement
• Destiny Tech100 Inc. Reports Second Quarter 2026 Results